#antibody-drug conjugate #Discovery Life Sciences #Xtalks

Accelerate Your Antibody-Drug Conjugate Development

In the world of oncology, Antibody-Drug Conjugates (ADCs) represent a cutting-edge therapeutic modality, yet their development is fraught with challenges. Aiming to address these issues, an upcoming free webinar hosted by Xtalks invites participants to delve into the intricacies of ADC development and why a “fail faster” strategy is crucial for success.

This session aims to equip researchers and professionals with the insights needed to navigate the complex landscape of ADCs. Participants will learn how conducting early in vitro tests can effectively identify both on-target efficacy and potential off-target toxicity risks. The involved methodologies promise to significantly enhance the rates of success in ADC development, ultimately driving down late-stage attrition rates.

What's on the Agenda?

During this engaging session, attendees will gain knowledge about the vital role of tumor-specific antibodies, linking mechanisms, and payload selection in determining the effectiveness and safety of ADCs. Crucially, the webinar will shed light on how tumoroid models can provide key physiological insights into ADC activity across various tumor types, thus offering more relevant data than conventional two-dimensional models.

Speakers will include Dr. Emer Clarke and Dr. Shawn Fahl from Discovery Life Sciences, both renowned experts in the field. They will share their expertise on how to leverage these innovative testing approaches effectively. Through the exploration of hematopoietic assays that predict off-target effects, such as myelosuppression and neutropenia, attendees will gain a comprehensive understanding of how to handle and mitigate these potential complications.

Practical Strategies for Success

Commonly, ADCs face significant risks stemming from their high upfront investments and low clinical success rates. To combat these risks, the webinar focuses on practical strategies to